Robert W. Shafer

25.2k total citations · 6 hit papers
268 papers, 17.3k citations indexed

About

Robert W. Shafer is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Robert W. Shafer has authored 268 papers receiving a total of 17.3k indexed citations (citations by other indexed papers that have themselves been cited), including 238 papers in Infectious Diseases, 207 papers in Virology and 38 papers in Epidemiology. Recurrent topics in Robert W. Shafer's work include HIV/AIDS drug development and treatment (216 papers), HIV Research and Treatment (207 papers) and HIV/AIDS Research and Interventions (138 papers). Robert W. Shafer is often cited by papers focused on HIV/AIDS drug development and treatment (216 papers), HIV Research and Treatment (207 papers) and HIV/AIDS Research and Interventions (138 papers). Robert W. Shafer collaborates with scholars based in United States, United Kingdom and Switzerland. Robert W. Shafer's co-authors include Soo‐Yon Rhee, Bryan Chan, Jonathan Schapiro, Mark A. Winters, David Katzenstein, Tommy F. Liu, Michele W. Tang, Deenan Pillay, Gregory K. Robbins and Roger Paredes and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Robert W. Shafer

263 papers receiving 16.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database

1999 763 citations Robert W. Shafer et al. profile →
Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update

2009 731 citations Rami Kantor, Michael R. Jordan et al. PLoS ONE profile →
The biological and clinical significance of emerging SARS-CoV-2 variants

2021 626 citations Kaiming Tao, Philip L. Tzou et al. profile →
Web Resources for HIV Type 1 Genotypic-Resistance Test Interpretation

2006 494 citations Robert W. Shafer et al. Clinical Infectious Diseases profile →
2015 update of the drug resistance mutations in HIV-1

2015 288 citations Vincent Cálvez, Victoria A. Johnson et al. PubMed profile →
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome is common in post-acute sequelae of SARS-CoV-2 infection (PASC): Results from a post-COVID-19 multidisciplinary clinic

2023 71 citations Hector Bonilla, Mitchell G. Miglis et al. profile →

Peers

Countries citing papers authored by Robert W. Shafer

Since Specialization

Citations

This map shows the geographic impact of Robert W. Shafer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert W. Shafer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert W. Shafer more than expected).

Fields of papers citing papers by Robert W. Shafer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert W. Shafer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert W. Shafer. The network helps show where Robert W. Shafer may publish in the future.

Co-authorship network of co-authors of Robert W. Shafer

This figure shows the co-authorship network connecting the top 25 collaborators of Robert W. Shafer. A scholar is included among the top collaborators of Robert W. Shafer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert W. Shafer. Robert W. Shafer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	GenBank2PubMed: bridging viral genomic data and the scientific literature with AI-assisted curation 2025 ·Scientific Reports ·Kaiming Tao, (unknown), (unknown), Robert W. Shafer	0
2	Utilizing HIV Proviral DNA to Assess for the Presence of HIV Drug Resistance 2025 ·Clinical Infectious Diseases ·Annemarie M. J. Wensing, Charlotte Charpentier, Vincent Cálvez, Francesca Ceccherini‐Silberstein, Huldrych F. Günthard, Donna M. Jacobsen, Roger Paredes, Robert W. Shafer, Douglas D. Richman	6
3	Comprehensive database of HIV mutations selected during antiretroviral in vitro passage experiments 2024 ·Antiviral Research ·Kaiming Tao, (unknown), (unknown), Philip L. Tzou, Robert W. Shafer	4
4	Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review 2024 ·Viruses ·Carolyn Chu, Kaiming Tao, (unknown), Ava Avalos, Jake Scott, Philip Grant, Soo‐Yon Rhee, Suzanne M. McCluskey, Michael R. Jordan, Rebecca L. Morgan, Robert W. Shafer	23
5	Post-COVID-19 Vaccination and Long COVID: Insights from Patient-Reported Data 2024 ·Vaccines ·(unknown), Mitchell G. Miglis, Lü Tian, Hector Bonilla, Phillip Yang, (unknown), (unknown), (unknown), (unknown), Robert W. Shafer, Linda N. Geng	1
6	Human immunodeficiency virus 1 5′-leader mutations in plasma viruses before and after the development of reverse transcriptase inhibitor-resistance mutations 2023 ·Journal of General Virology ·Janin Nouhin, Philip L. Tzou, Soo‐Yon Rhee, Malaya K. Sahoo, Benjamin A. Pinsky, Miri Krupkin, Joseph D. Puglisi, Elisabetta Viani Puglisi, Robert W. Shafer	0
7	HIV-1 Group M Capsid Amino Acid Variability: Implications for Sequence Quality Control of Genotypic Resistance Testing 2023 ·Viruses ·Kaiming Tao, Soo‐Yon Rhee, Philip L. Tzou, (unknown), Sergei L. Kosakovsky Pond, Susan Holmes, Robert W. Shafer	5
8	Adherence to contemporary antiretroviral treatment regimens and impact on immunological and virologic outcomes in a US healthcare system 2022 ·PLoS ONE ·(unknown), Soo‐Yon Rhee, C. Bradley Hare, Robert W. Shafer, Kristin L. Sainani	21
9	Integrase Strand Transfer Inhibitor Resistance in Integrase Strand Transfer Inhibitor-Naive Persons 2021 ·AIDS Research and Human Retroviruses ·(unknown), Soo‐Yon Rhee, Robert W. Shafer	11
10	In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations 2020 ·Journal of Antimicrobial Chemotherapy ·Francesco Saladini, (unknown), (unknown), (unknown), Adele Boccuto, Filippo Dragoni, Ilaria Vicenti, Robert W. Shafer, Maurizio Zazzi	15
11	Moderate-to-High Levels of Pretreatment HIV Drug Resistance in KwaZulu-Natal Province, South Africa 2018 ·AIDS Research and Human Retroviruses ·Benjamin Chimukangara, Ayesha B. M. Kharsany, Richard Lessells, Kogieleum Naidoo, Soo‐Yon Rhee, Justen Manasa, Tiago Gräf, Lara Lewis, Cherie Cawood, David Khanyile, Karidia Diallo, Kassahun Ayalew, Robert W. Shafer, Gillian Hunt, Deenan Pillay, (unknown), Túlio de Oliveira	23
12	HIV-1 Protease, Reverse Transcriptase, and Integrase Variation 2016 ·Journal of Virology ·Soo‐Yon Rhee, Kris Sankaran, Vici Varghese, Mark A. Winters, Christopher B. Hurt, Joseph J. Eron, Neil Parkin, Susan Holmes, Mark Holodniy, Robert W. Shafer	68
13	2015 Update of the Drug Resistance Mutations in HIV-1. 2016 ·PubMed ·Annemarie M. J. Wensing, Vincent Cálvez, Huldrych F. Günthard, Victoria A. Johnson, Roger Paredes, Deenan Pillay, Robert W. Shafer, Douglas D. Richman	56
14	2017 Update of the Drug Resistance Mutations in HIV-1. 2016 ·PubMed ·Annemarie M. J. Wensing, Vincent Cálvez, Huldrych F. Günthard, Victoria A. Johnson, Roger Paredes, Deenan Pillay, Robert W. Shafer, Douglas D. Richman	149
15	HIV-1 Integrase Sequence Variability in Antiretroviral Naïve Patients and in Triple-Class Experienced Patients Subsequently Treated with Raltegravir 2010 ·AIDS Research and Human Retroviruses ·Vici Varghese, Tommy F. Liu, Soo‐Yon Rhee, (unknown), (unknown), W. Jeffrey Fessel, Robert W. Shafer	28
16	O desafio da resistência à medicação antirretroviral em crianças infectadas pelo HIV-1 2009 ·Jornal de Pediatria ·Robert W. Shafer	1
17	Minority Human Immunodeficiency Virus Type 1 Variants in Antiretroviral-Naive Persons with Reverse Transcriptase Codon 215 Revertant Mutations 2008 ·Journal of Virology ·Yumi Mitsuya, Vici Varghese, Chunlin Wang, Tommy F. Liu, Susan Holmes, (unknown), Baback Gharizadeh, Mostafa Ronaghi, Daniel B. Klein, W. Jeffrey Fessel, Robert W. Shafer	63
18	Protease and Reverse Transcriptase Mutation Patterns in HIV Type 1 Isolates from Heavily Treated Persons: Comparison of Isolates from Northern California with Isolates from Other Regions 2003 ·AIDS Research and Human Retroviruses ·Matthew J. Gonzales, (unknown), Kathryn Dupnik, Soo‐Yon Rhee, Robert W. Shafer	10
19	Determination of the optimal cut-offs for predicting the phenotype of nine different HIV drug-resistance algorithms 2002 ·Antiviral Therapy ·(unknown), Bárbara Schmidt, Klaus Korn, Wilco Keulen, (unknown), Niko Beerenwinkel, Joachim Selbig, Anne–Mieke Vandamme, (unknown), Robert W. Shafer, (unknown), Ronan Boulmé, (unknown), (unknown)	1
20	HIV-1 Subtype C Reverse Transcriptase and Protease Genotypes in Zimbabwean Patients Failing Antiretroviral Therapy 2002 ·AIDS Research and Human Retroviruses ·Rami Kantor, Lynn S. Zijenah, Robert W. Shafer, (unknown), Elizabeth Johnston, Robert M. Lloyd, (unknown), Dennis Israelski, David Katzenstein	50

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact